Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab

J Investig Allergol Clin Immunol. 2022 Dec 15;32(6):504-506. doi: 10.18176/jiaci.0796. Epub 2022 Feb 28.

Authors

C Picado^{1

2}, Jr Jm Mascaró^{1

2

3}, A Vlagea⁴, M Pascal^{1

2

4}, R Muñoz-Cano^{1

2

5}, J Bartra^{1

2

5}

Affiliations

¹ Hospital Clinic, University of Barcelona, Barcelona, Spain.
² Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain.
³ Department of Dermatology, Hospital Clinic, Barcelona, Spain.
⁴ Department of Immunology, CDB, Hospital Clinic, Barcelona, Spain.
⁵ Department of Allergy, Hospital Clinic, Barcelona, Spain.

PMID: 35225792
DOI: 10.18176/jiaci.0796

No abstract available

Keywords: Angioedema; Immunodeficiency; Immunoglobulin E; Omalizumab; Urticaria.

MeSH terms

Anti-Allergic Agents* / therapeutic use
Chronic Disease
Chronic Urticaria* / drug therapy
Humans
Immunoglobulin E
Omalizumab / therapeutic use
Treatment Outcome
Urticaria* / drug therapy

Substances

Omalizumab
Anti-Allergic Agents
Immunoglobulin E